Inoviq (ASX:IIQ) Net Income (Continuing Operations): A$-7.24 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IIQ Inoviq Ltd ASX:IIQ
14 GF Score
Price A$0.20
GF Value A$0.52
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Inoviq Net Income (Continuing Operations)?

Inoviq ASX:IIQ +2.63% 14 Net Income (Continuing Operations) is A$-7.24 Mil as of Dec. 2025. GuruFocus rates ASX:IIQ with a GF Score™ of 14/100 and a GF Value™ of A$0.52 (Possible Value Trap). The stock has 2 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Inoviq's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was A$-3.96 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-7.24 Mil.

Inoviq  (ASX:IIQ) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Inoviq Net Income (Continuing Operations) Related Terms

Inoviq Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Inoviq's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inoviq Net Income (Continuing Operations) Chart

Inoviq Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.37 -18.20 -8.97 -6.55 -6.93

Inoviq Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.13 -3.43 -3.65 -3.28 -3.96
ASX:IIQ
14GF Score
Inoviq Ltd ASX:IIQ
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inoviq Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-7.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of A$-7.24 Mil mean?
Inoviq (ASX:IIQ) has a Net Income (Continuing Operations) of A$-7.24 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Inoviq and its competitors.
Is Inoviq's Net Income (Continuing Operations) too high?
Inoviq's current Net Income (Continuing Operations) is A$-7.24 Mil. Overall, Inoviq has a GF Score™ of 14/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's Net Income (Continuing Operations) compare to TMO and DHR?
Inoviq's Net Income (Continuing Operations) of A$-7.24 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Diagnostics & Research company?
A good Net Income (Continuing Operations) depends on the Medical Diagnostics & Research industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Inoviq and its competitors. Inoviq's current Net Income (Continuing Operations) is A$-7.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.52, compared to a current price of A$0.20 — trading 62.5% below its estimated fair value. The current Net Income (Continuing Operations) is A$-7.24 Mil. Inoviq's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current Net Income (Continuing Operations) is A$-7.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inoviq (ASX:IIQ) Overvalued in 2026?

Based on GuruFocus' analysis, Inoviq stock appears to be undervalued. The current stock price of A$0.20 is trading 62.5% below its estimated GF Value™ of A$0.52. GuruFocus considers Inoviq to be Possible Value Trap.

Key valuation signals for ASX:IIQ:

  • Net Income (Continuing Operations): A$-7.24 Mil
  • GF Value™: A$0.52 vs. price of A$0.20 (62.5% below fair value)
  • GF Score™: 14/100 with 2 warning signs

No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inoviq Business Description

Other Exchanges EGQ0:GermanyEGQ0:Germany
Address 23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
14GF Score

Get the complete analysis for ASX:IIQ

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.20
Price
A$0.52
GF Value